Company: Aptamer Group (APTA)
Date: 06 December 2022
Company Information: Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer® platform.
Optimer® binders are oligonucleotide affinity ligands that can serve as antibody alternatives in a variety of applications across different life science sectors. The global antibody market is currently worth over $145.0 billion. Optimer® binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists
Dr Arron Tolley, CEO
Arron holds a Ph.D. in Molecular Biology and Biophysics and a B.Sc. in Molecular Medicine from the University of Leeds. Arron has several years’ experience raising aptamers against complex cellular targets and model disease systems. He has developed several aptamer panels against model cell lines associated with oesophageal adenocarcinoma. These have shown promise for use as cell imaging reagents, biomarker discovery tools and as novel therapeutics. Arron still plays an active role in the R&D side of Aptamer Group and is credited with the invention and development of a new Aptamer-based biomarker discovery platform to be offered to the life sciences industry through the Aptamer Group.
Jenny Cutler, Interim CFO
Jenny is a Chartered Accountant (FCA) with over 20 years of finance leadership experience and has worked at AIM and Main Listed businesses. Most recently, Jenny was Chief Financial Officer of Fulcrum Utility Services Limited (AIM) and was previously Director of Finance and Interim Finance Director at Harworth Group plc (Main Market (premium)). She is currently acting as Interim Chief Financial Officer for Aptamer Group and is responsible for the day-to-day financial management of the Group including reporting to the Board on matters of financial performance and control.
Dr David Bunka, Chief Technical Officer
David holds a Ph.D. in Molecular Biology and has spent nearly 20 years developing nucleic acid aptamers against a wide variety of targets including small molecules (antibiotics, food contaminants, chemotherapeutics), disease-associated proteins, several cancer-associated cell-lines, viruses and tissue biopsies. This work has been facilitated through the use of high-throughput, automated aptamer selection methods. David has built up an established international reputation in the field and has authored several peer-reviewed research articles, invited review articles and a book chapter on aptamer-based therapeutics. He has also given many guest seminars covering aptamer-based applications at top universities and international conferences.
If you are already a member of ShareSoc you must log in prior to registering, then just click “REGISTER” below. If you are not already a member of ShareSoc, please complete the form below to sign up as an Associate member and then click “REGISTER”.
Click here for help on logging in.
Once you have registered you will receive an email notification, as well as reminders 1 day and 1 hour before the event starts.